Zymeworks Announces Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

VANCOUVER, British Columbia & SEATTLE — Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced, in conjunction with its Asia Pacific partner BeiGene, the acceptance of two abstracts for poster presentations at the upcoming 2022 ASCO Annual Meeting taking place virtually and in Chicago, IL from June 3 – 7, 2022. The presentations will provide new clinical data from two early-stage studies of zanidatamab in first-line oncology settings. Read More